Rifaximin in irritable bowel syndrome: Rationale, evidence and clinical use

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 2, 2013, Pages 71-75

  Saadi, Mohammed ^a   Mccallum, Richard W ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Irritable bowel syndrome; Lactulose breath test; Microbiome; Rifaximin; Small intestinal bacterial overgrowth

Indexed keywords

GLUCOSE; LACTULOSE; NEOMYCIN; PLACEBO; RIFAXIMIN;

BACTERIAL OVERGROWTH; BLOATING; BREATH ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FLATULENCE; HUMAN; INTESTINE FLORA; IRRITABLE COLON; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

EID: 84875513134     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312472008     Document Type: Article

References (18)

1. Azpiroz F. Bouin M. Camilleri M. Mayer E. Poitras P. Serra J. et al. (2007) Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 19: 62–88.
2. Carroll I. Ringel-Kulka T. Siddle J. Ringel Y. (2012) Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24: 521–530.
3. Eckburg P. Bik E. Bernstein C. Purdom E. Dethlefsen L. Sargent M. et al. (2005) Diversity of the human intestinal microbial flora. Science 308: 1635–1638.
4. Ghoshal U. (2011) How to interpret hydrogen breath tests. J Neurogastroenterol Motil 2011; 17 (3): 312–317.
5. Jolley J. ( 2011) High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 4: 43–48.
6. Kim J. Lin H. (2007) Contribution of gut microbes to GI motility disorder. Pract Gastroenterol. GI motility, A series from AMS.
7. Lauritano E. Gabrielli M. Scarpellini E. Lupascu A. Novi M. Sottili S. et al. (2008) Small intestinal overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 103: 2031–2035.
8. Levitt M. (1969) Production and excretion of hydrogen gas in man. N Engl J Med 281: 122–127.
9. Longstreth G. Thompson W. Chey W. Houghton L. Mearin F. Spiller R. (2006) Functional bowel disorders. Gastroenterology 130: 1480–1491.
10. Majewski M. Reddymasu S. Sostarich S. Foran P. McCallum R. (2007) Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 333: 266–270.
11. Pimentel M. Chow E. Lin H. (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: 412–419.
12. Pimentel M. Lembo A. Chey W. Zakko S. Ringel Y. Yu J. et al. TARGET Study Group (2011 a) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: 22–32.
13. Pimentel M. Lezcano S. (2007) Irritable bowel syndrome: bacterial overgrowth – what's known and what to do. Curr Treat Options Gastroenterol 10: 328–337.
14. Pimentel M. Morales W. Chua K. Barlow G. Weitsman S. Kim G. et al. (2011 b) Effects of rifaximin treatment and retreatment in non-constipated IBS subjects. Dig Dis Sci 56: 2067–2072.
15. Quigley E. Quera R. (2006) Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 130(2 Suppl. 1): S78–S90.
16. Schoepfer A. (2012) Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36 (11): 1084–1093.
17. Talley N. (2006) Irritable bowel syndrome. Intern Med J 36: 724–728.
18. Yang J. Lee H. Low K. Chatterjee S. Pimentel M. (2008) Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 53: 169–174.